The investigator's long-term goal is to conduct Naloxone for Opioid Associated out of Hospital Cardiac Arrest (NOPACA), a randomized, double blind, controlled trial to determine the efficacy of naloxone vs. placebo in Opioid Associated out of Hospital Cardiac Arrest. The investigative team plan to randomize patients in OHCA to early naloxone administration vs. placebo after initial resuscitation and measure ROSC and survival. Challenges to designing NOPACA include uncertainty regarding: 1) the available pool of participants and number of EMS agencies needed to meet enrollment targets; 2) acceptability among patients, EMS and Emergency Medicine provider stakeholders, and 3) estimates of the study outcomes needed for sample size estimates. Toward obtaining the necessary information to design NOPACA, the investigators propose a pilot RCT of participants at high risk for OA-OHCA to verify a reasonable recruitment rate; treatment fidelity and acceptability; and adequate retention and measurement of outcomes at follow up. The investigators propose incorporating hypothesis testing of the feasibility outcomes to determine progression to a definitive trial.

开始日期2026-11-01

申办/合作机构

The University of California, San Francisco

NCT04650841

/ Not yet recruiting早期临床1期IIT

The Role of the Opioid System in Placebo Effects on Pain and Social Rejection

The current study probes the involvement of the opioid system in placebo effects on social pain, using the opioid antagonist naloxone. 60 participants who recently experienced an unwanted breakup will experience rejection-related stimuli and receive painful heat and pressure stimuli during fMRI scanning. Participants will be randomized to receive either a naloxone or saline nasal spray, and be informed that the spray is either saline, or an effective pain and negative emotion reducing agent.

开始日期2026-09-01

申办/合作机构

Trustees of Dartmouth College

NCT07459166

/ Not yet recruiting临床2期

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of a Single Dose of Intravenous CS 1103 Following a Single Intravenous Dose of Fentanyl in Healthy Subjects With Naloxone Blockade

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of CS-1103 (1,000 mg), given by intravenous (IV) infusion in healthy participants in the presence of a clinically relevant dose of fentanyl (200 μg, IV), with naloxone blockade (400 μg, IV).

开始日期2026-04-01

申办/合作机构

Clear Scientific, Inc.

[+1]

100 项与盐酸纳洛酮相关的临床结果

登录后查看更多信息

100 项与盐酸纳洛酮相关的转化医学

登录后查看更多信息

100 项与盐酸纳洛酮相关的专利（医药）

登录后查看更多信息

25,421

项与盐酸纳洛酮相关的文献（医药）

2026-12-01·JOURNAL OF CONTINUING EDUCATION IN THE HEALTH PROFESSIONS

Enhancing Naloxone Reach Through Innovative Training Strategies at an Academic Medical Center in Arkansas

Article

作者: Williams, Adrian J ; Breckling, Meghan ; Tobey-Moore, Leah

Abstract::

The Arkansas Naloxone Education and Training (ANET) program, based at the University of Arkansas for Medical Sciences, was developed to address the urgent need for opioid-overdose prevention across the state. Funded by the Substance Abuse and Mental Health Administration (SAMHSA), ANET uses a train-the-trainer model to equip health care professionals with the knowledge and tools necessary to deliver naloxone education in their local settings. In its first year, the program launched a three-module curriculum, accredited for continuing education, of health care professionals and delivered using an academic detailing teaching strategy, prioritized recruitment from counties through a needs assessment including the highest rates of opioids dispensed and of overdose deaths, and implemented a comprehensive evaluation plan that is grounded in an evidence-based framework that facilitates continuous evaluation and improvement (ie, RE-AIM framework—Reach, Effectiveness, Adoption, Implementation, and Maintenance). Knowledge and attitudes were assessed before and after health care professionals completed the training program. All trainers received technical support and outreach materials. The program also fostered strategic statewide partnerships to support recruitment, implementation, and community engagement. ANET is embedded within an academic medical center and aligned with continuing professional development infrastructure, offering a replicable model for community-centered overdose prevention. Lessons learned during the program's implementation underscore its potential to inform future design, delivery, and sustainability of similar interventions.

2026-06-01·Addictive behaviors reports

Substance use treatment and overdose patterns in high and low social vulnerability counties: a trends analysis in New Jersey from 2014–2022

Article

作者: Fougnies, Lara V ; Hilton, Katie ; Juntilla, Alyssa M ; Lister, Jamey J ; Cooper, Sarah E ; Lister, Holly H

Introduction:

This study investigates trends in substance use treatment admissions and overdose patterns across New Jersey counties from 2014 to 2022. Using the Social Vulnerability Index (SVI), we examined how county-level vulnerability differentiates treatment utilization and overdose outcomes.

Materials and Methods:

We created a novel, longitudinal data set using data from multiple public sources. Data were obtained and analyzed for all 21 New Jersey counties. Outcome measures included substance use treatment admissions, opioid-specific treatment admissions, overdose deaths, and naloxone administration. Using the SVI, counties were categorized as either high (n = 10) or low (n = 11) social vulnerability. Data analyses were conducted using joinpoint analysis to identify trends over time and variation by social vulnerability status.

Results:

Significant trends were identified regardless of social vulnerability status for all outcome measures, appearing as upward trends in initial segments and flat or declining trends in latter segments. High vulnerability (compared to low vulnerability) counties demonstrated greater Annual Percentage Change (APC) magnitudes for all outcome measures in the initial segment, similar APCs in the latter segment, and had higher baseline rates and peak rates.

Conclusions:

Findings demonstrate that county-level social vulnerability status is associated with substance use treatment admissions and overdose patterns. Specifically, high vulnerability counties exhibit consistently higher rates of substance use treatment admissions, naloxone administrations, and overdose deaths. This pattern highlights a need for expanded substance use services along the continuum of care for vulnerable areas and the viability of SVI status as a useful and simple tool for targeting service expansion efforts.

2026-06-01·Addictive behaviors reports

Treatment preferences of patients receiving opioid agonist therapy in spain: a discrete choice experiment

Article

作者: Gómez-Barrera, M ; Yébenes Cortés, M ; Henche Ruíz, A I ; Sánchez Máñez, A ; Rodríguez Cejas, M A ; Dorado García, M L ; Palma Álvarez, R F ; Vega Astudillo, P ; Orengo Caus, T ; Alonso Ganuza, Z ; Crespo Portero, A ; Marcos Flores, A ; Sucunza Guibert, D

Aim:

To explore the preferences of patients with opioid use disorder (OUD) regarding opioid agonist treatment (OAT).

Methods:

The present study was a descriptive, observational, cross-sectional study in OUD patients on treatment for at least 3 months, using one of the pharmacological options available in Spain: methadone (MTD) tablets, MTD oral solution, sublingual buprenorphine/naloxone (SL BPN/NX) or long-acting injectable buprenorphine (LAIB). A discrete choice experiment (DCE) assessed which medication attributes patients prioritized when selecting a hypothetical ideal treatment for their disease.

Results:

128 patients from 10 different addiction centres (AC) participated in this study. Treatment groups were balanced: liquid MTD: 28.1%; LAIB: 25%; SL BPN/NX: 24.2%, and MTD tablets: 22.7%. The mean age of the patients was 51 years, and 80% were men. For the total sample, the frequency of administration (Relative importance [RI]: 42.07%) (monthly/weekly vs. daily), route of administration (RI: 22.12%) (oral/SL vs. injectable), and cost (RI = 19.38%) (no co-payment vs. co-payment) were the most impactful factors. For LAIB patients, frequency of administration was the most preferred attribute ahead of cost (second) and performance of daily activities (third). Administration route in these patients ranked fourth. Preferences for these criteria were equal between MTD and SL BPN/NX.

Conclusion:

Frequency of administration was the main attribute across all treatment groups. Among patients treated with MTD or SL BPN/NX, route of administration and cost were the second and third most relevant attributes, whereas in LAIB patients, cost and the impact on daily activities ranked second and third, respectively.

748

项与盐酸纳洛酮相关的新闻（医药）

2026-03-16

·Risk at Value

【2026关注公司每周重要信息3月9日-3月15日】

华测导航为促进长远发展，通过全资主体宁波熙禾投资管理合伙企业(有限合伙)于近期与苏州方广三期创业投资管理合伙企业(有限合伙)等共同投资成立杭州方广熙禾创业投资合伙企业(有限合伙)，近日，产业基金已完成工商登记手续并取得营业执照。产业基金认缴出资总额为人民币 25,200万元，其中宁波熙禾以自有资金认缴出资12,500万元，占产业基金认缴出资总额的49.60%。产业基金成立于2026年2月13日，执行事务合伙人为苏州方广三期创业投资管理合伙企业(有限合伙)。巨星科技 3月10日接到公司副总裁、董事会秘书周思远先生的通知，周思远先生基于对公司未来发展前景的信心和对公司股票长期投资价值的认可，通过集中竞价方式增持100000股，增持均价为31.50元/股，增持后持股数量为475000股，持股比例为0.0398%，增持前持股数量为375000股，持股比例为0.0314%。小熊电器业绩快报。2025年实现营业收入52.35亿元，同比增长10%；归属于上市公司股东的净利润为4亿元，同比增长39.17%；扣除非经常性损益后净利润为3.61亿元，同比增长46.66%。 Q4单季度收入15.44亿元，同比-4.6%，扣非净利润1.34亿元，同比+11.7%。略低于预期，作为对比，25Q2收入同比+30%，扣非利润+657%，Q3收入同比+17%，扣非净利润同比+1018%，前三季度业绩增长主要靠并表罗曼智能以及基数非常低，Q4收入同比下滑主要是并表效应过去（罗曼智能是24年7月开始并表），而扣非利润增速大幅放缓，除了并表因素消失外更重要的是24Q4基数很高（24Q4扣非利润1.2亿，同比+6%，而24Q3只有351万，同比-75.6%）。目前PE 19倍不到，股息率2.4%，对比同行还是不够便宜啊。中国生物制药正大天晴自主研发的1类创新药TQB3205“pan-KRAS抑制剂”已获得中国国家药品监督管理局(NMPA)的临床试验批准，拟用于治疗晚期恶性肿瘤。 TQB3205是一款口服的pan-KRAS抑制剂，其核心作用机制是与多种KRAS突变蛋白高亲和力结合，通过抑制SOS1介导的KRAS核苷酸交换，阻断RAS激活，抑制下游ERK磷酸化，从而有效抑制多种KRAS突变肿瘤细胞的增殖。 KRAS基因是RAS家族中突变频率最高的基因。全球约30%的癌症病例与RAS基因突变相关，其中由KRAS突变导致的癌症占所有RAS突变的85%，在胰腺癌(90%)、结直肠癌(30%-50%)、非小细胞肺癌(15%-20%)等多种癌症中普遍存在。常见的KRAS突变亚型包括G12C、G12V、G12D、G13D等。目前全球已获批上市的5款KRAS抑制剂均仅针对G12C单一突变亚型。而pan-KRAS抑制剂旨在克服现有KRAS抑制剂仅针对单一突变（如G12C）的局限性。 pan-KRAS抑制剂也是加科思的核心产品线，这里稍微多说一句，加科思之前我也略有关注，刚好年报出来了，他的pan-KRAS抑制剂早期临床数据也出来了，是非常不错。加科思是典型的优质小型biotech公司，因为规模小，只能是集中力量“小投资”在少数管线上，押注它成为大单品大回报。目前才55亿港币市值，不过压力也不小，正大天晴的研发、临床乃至销售、BD等能力显然要强于加科思好几个数量级。艾德生物业绩快报。2025年收入同比+8%至11.98亿，净利润同比+40.4%至3.58亿，扣非净利润同比+44.9%至3.38亿。 Q4单季度收入3.32亿，同比+27%，环比+16%，扣非净利润0.88亿，同比+319%，环比+29.8%。Q4业绩同比和环比增速均较高，主要是基数问题和订单后置确认带来的（之前在Q3财报的解读中已经说过Q4因为基数问题业绩会很好看），24Q4营收和扣非净利润分别同比-22.3%、-75.3%，而24年前三季度收入和利润增速分别为20%和38%，还有25Q3收入和扣非利润的增速分别为-6%、-18%，而25上半年分别为+6.7%和+40%。从历史数据看，25Q4收入和利润基本和23Q4接近，在整个行业大环境弱于23年的情况下，这个业绩还算可以了，一方面是多项新产品上市，一方面是公司加大了海外市场的销售，一方面是三季度部分收入推迟到了Q4确认（Q3业绩异常低的原因），股价一直在底部横盘，PE 22倍，也不算特别便宜，可能会因为Q4还算可以的业绩反弹一波，但想走出底部形成上涨趋势，暂时看缺乏催化剂。中国生物制药正大天晴自主研发的国家1类创新药TQB3454“IDH1抑制剂”治疗伴IDH1突变晚期胆道癌III期临床研究已完成方案预设的期中分析，IDMC判定主要研究终点无进展生存期(PFS)、总生存期(OS)均达到方案预设的优效界值。本集团已与CDE就该适应症的上市申请进行沟通,并获得CDE书面同意,将于近期递交上市申请。这是全球第2个、国内第1个IDH1抑制剂在胆道癌取得成功的III期临床研究。 TQB3454已于2023年4月被CDE纳入突破性治疗药物程序。此次III期临床研究取得积极成果,将进一步加速其上市进程,有望尽快为胆管癌患者提供新的治疗选择。绿叶制药与国药控股股份有限公司及其子公司国药集团药业股份有限公司正式签署战略合作协议。三方将围绕包括米美欣®（羟考酮纳洛酮缓释片）在内的绿叶制药多款产品，在渠道布局、市场准入、资源协同等方面展开全方位合作。此次战略合作将整合绿叶制药的产品优势与国药体系的供应链优势，推动优质产品触达全域市场，助力绿叶制药在构建高效商业化体系上迈出关键一步。米美欣®适用于成人需阿片类镇痛药才能充分控制的重度疼痛；通过加入阿片受体拮抗剂纳洛酮，能够阻断羟考酮对肠道阿片受体的作用，从而有效缓解阿片类药物引起的便秘症状。羟考酮纳洛酮缓释片是国内首个填补口服纳洛酮制剂空白的镇痛药物，也是国内唯一兼具强效镇痛和从机制上解决阿片类药物引起便秘问题的创新组合。针对麻精药品的监管要求与临床需求，三方将合力打造定制化的分销与学术推广体系，依托国药体系成熟的全国分销网络，协同国药体系内的产品矩阵，助力米美欣®惠及更多患者。康方生物 3月初，康方生物其全球首个ILT2/ILT4/CSF1R三靶点抗体AK150拿到了国家药监局的临床许可，将在晚期实体瘤患者中启动试验。随后，公司宣布叫停抗CD73单抗AK119与依沃西联合用于二线肺癌的临床项目，官方说法是“研发战略优先级调整”。在肿瘤免疫治疗的热门靶点赛道中，CD73曾被寄予厚望，一度被认为是破解肿瘤免疫逃逸的重要突破口。目前，康方还有AK131（靶向CD73和PD-1）和AK137（靶向CD73和Lag3）两个双抗项目正在中国进行1期临床试验。在1/2期（也就是刚看到初步疗效数据的阶段）就叫停，大概率是因为加上CD73单抗后，疗效并没有比单独使用AK112有显著提升，甚至可能增加了不必要的毒副作用。既然联合用药不能带来“碾压级”的数据，继续往下做三期临床就毫无胜算。本质上就是CD73这个靶点很可能是失败的方向（单抗之前数据不行，联用数据也不好，类似之前著名的失败的CD47靶点）。与此同时，野村东方国际证券将康方目标价从120.64港元下调至112.73港元，理由是PD-1/VEGF双抗赛道的竞争优势正在收缩。按野村的预测，公司2025年全年收入规模大约在33亿元人民币，与管理层此前公开的40亿元目标之间，还差着不小的距离。三生制药旗下子公司浙江三生蔓迪药业有限公司向国家药品监督管理局（NMPA）提交的艾曲泊帕乙醇胺片的上市申请已于日前获得批准，批准适应症为：（1）本品适用于既往对糖皮质激素、免疫球蛋白等治疗反应不佳的成人和6岁及以上儿童慢性免疫性（特发性）血小板减少症（ITP）患者，使血小板计数升高并减少或防止出血。本品仅用于因血小板减少和临床条件导致出血风险增加的ITP患者；（2）本品适用于既往对免疫抑制治疗缓解不充分的重型再生障碍性贫血（SAA）患者。这是公司在血液领域赛道的又一重要进展，为广大患者带来更多的选择和获益。自主研发的SSS67正式获得美国食品药品监督管理局的IND（新药临床试验申请）批准，标志着这款创新型靶向ActRIIA/ActRIIB的双特异性抗体药物正式迈入临床阶段。这是公司在代谢疾病领域的又一重要进展，将为超重/肥胖症患者带来全新治疗选择。 SSS67是公司依托内部抗体发现平台开发的一款四价双特异性抗体药物，能够实现同时结合ActRIIA和ActRIIB受体，通过调控脂肪代谢与肌肉合成相关通路，从而实现减脂与增加肌肉质量双重效果。

2026-03-16

·雪球

【2026关注公司每周重要信息3月9日-3月15日】华测导航为促进长远发展

【2026关注公司每周重要信息3月9日-3月15日】华测导航为促进长远发展，通过全资主体宁波熙禾投资管理合伙企业(有限合伙)于近期与苏州方广三期创业投资管理合伙企业(有限合伙)等共同投资成立杭州方广熙禾创业投资合伙企业(有限合伙)，近日，产业基金已完成工商登记手续并取得营业执照。产业基金认缴出资总额为人民币25,200万元，其中宁波熙禾以自有资金认缴出资12,500万元，占产业基金认缴出资总额的49.60%。产业基金成立于2026年2月13日，执行事务合伙人为苏州方广三期创业投资管理合伙企业(有限合伙)。巨星科技3月10日接到公司副总裁、董事会秘书周思远先生的通知，周思远先生基于对公司未来发展前景的信心和对公司股票长期投资价值的认可，通过集中竞价方式增持100000股，增持均价为31.50元/股，增持后持股数量为475000股，持股比例为0.0398%，增持前持股数量为375000股，持股比例为0.0314%。小熊电器业绩快报。2025年实现营业收入52.35亿元，同比增长10%；归属于上市公司股东的净利润为4亿元，同比增长39.17%；扣除非经常性损益后净利润为3.61亿元，同比增长46.66%。Q4单季度收入15.44亿元，同比-4.6%，扣非净利润1.34亿元，同比+11.7%。略低于预期，作为对比，25Q2收入同比+30%，扣非利润+657%，Q3收入同比+17%，扣非净利润同比+1018%，前三季度业绩增长主要靠并表罗曼智能以及基数非常低，Q4收入同比下滑主要是并表效应过去（罗曼智能是24年7月开始并表），而扣非利润增速大幅放缓，除了并表因素消失外更重要的是24Q4基数很高（24Q4扣非利润1.2亿，同比+6%，而24Q3只有351万，同比-75.6%）。目前PE19倍不到，股息率2.4%，对比同行还是不够便宜啊。中国生物制药正大天晴自主研发的1类创新药TQB3205“pan-KRAS抑制剂”已获得中国国家药品监督管理局(NMPA)的临床试验批准，拟用于治疗晚期恶性肿瘤。TQB3205是一款口服的pan-KRAS抑制剂，其核心作用机制是与多种KRAS突变蛋白高亲和力结合，通过抑制SOS1介导的KRAS核苷酸交换，阻断RAS激活，抑制下游ERK磷酸化，从而有效抑制多种KRAS突变肿瘤细胞的增殖。KRAS基因是RAS家族中突变频率最高的基因。全球约30%的癌症病例与RAS基因突变相关，其中由KRAS突变导致的癌症占所有RAS突变的85%，在胰腺癌(90%)、结直肠癌(30%-50%)、非小细胞肺癌(15%-20%)等多种癌症中普遍存在。常见的KRAS突变亚型包括G12C、G12V、G12D、G13D等。目前全球已获批上市的5款KRAS抑制剂均仅针对G12C单一突变亚型。而pan-KRAS抑制剂旨在克服现有KRAS抑制剂仅针对单一突变（如G12C）的局限性。pan-KRAS抑制剂也是加科思的核心产品线，这里稍微多说一句，加科思之前我也略有关注，刚好年报出来了，他的pan-KRAS抑制剂早期临床数据也出来了，是非常不错。加科思是典型的优质小型biotech公司，因为规模小，只能是集中力量“小投资”在少数管线上，押注它成为大单品大回报。目前才55亿港币市值，不过压力也不小，正大天晴的研发、临床乃至销售、BD等能力显然要强于加科思好几个数量级。艾德生物业绩快报。2025年收入同比+8%至11.98亿，净利润同比+40.4%至3.58亿，扣非净利润同比+44.9%至3.38亿。Q4单季度收入3.32亿，同比+27%，环比+16%，扣非净利润0.88亿，同比+319%，环比+29.8%。Q4业绩同比和环比增速均较高，主要是基数问题和订单后置确认带来的（之前在Q3财报的解读中已经说过Q4因为基数问题业绩会很好看），24Q4营收和扣非净利润分别同比-22.3%、-75.3%，而24年前三季度收入和利润增速分别为20%和38%，还有25Q3收入和扣非利润的增速分别为-6%、-18%，而25上半年分别为+6.7%和+40%。从历史数据看，25Q4收入和利润基本和23Q4接近，在整个行业大环境弱于23年的情况下，这个业绩还算可以了，一方面是多项新产品上市，一方面是公司加大了海外市场的销售，一方面是三季度部分收入推迟到了Q4确认（Q3业绩异常低的原因），股价一直在底部横盘，PE22倍，也不算特别便宜，可能会因为Q4还算可以的业绩反弹一波，但想走出底部形成上涨趋势，暂时看缺乏催化剂。中国生物制药正大天晴自主研发的国家1类创新药TQB3454“IDH1抑制剂”治疗伴IDH1突变晚期胆道癌III期临床研究已完成方案预设的期中分析，IDMC判定主要研究终点无进展生存期(PFS)、总生存期(OS)均达到方案预设的优效界值。本集团已与CDE就该适应症的上市申请进行沟通,并获得CDE书面同意,将于近期递交上市申请。这是全球第2个、国内第1个IDH1抑制剂在胆道癌取得成功的III期临床研究。TQB3454已于2023年4月被CDE纳入突破性治疗药物程序。此次III期临床研究取得积极成果,将进一步加速其上市进程,有望尽快为胆管癌患者提供新的治疗选择。绿叶制药与国药控股股份有限公司及其子公司国药集团药业股份有限公司正式签署战略合作协议。三方将围绕包括米美欣®（羟考酮纳洛酮缓释片）在内的绿叶制药多款产品，在渠道布局、市场准入、资源协同等方面展开全方位合作。此次战略合作将整合绿叶制药的产品优势与国药体系的供应链优势，推动优质产品触达全域市场，助力绿叶制药在构建高效商业化体系上迈出关键一步。米美欣®适用于成人需阿片类镇痛药才能充分控制的重度疼痛；通过加入阿片受体拮抗剂纳洛酮，能够阻断羟考酮对肠道阿片受体的作用，从而有效缓解阿片类药物引起的便秘症状。羟考酮纳洛酮缓释片是国内首个填补口服纳洛酮制剂空白的镇痛药物，也是国内唯一兼具强效镇痛和从机制上解决阿片类药物引起便秘问题的创新组合。针对麻精药品的监管要求与临床需求，三方将合力打造定制化的分销与学术推广体系，依托国药体系成熟的全国分销网络，协同国药体系内的产品矩阵，助力米美欣®惠及更多患者。康方生物3月初，康方生物其全球首个ILT2/ILT4/CSF1R三靶点抗体AK150拿到了国家药监局的临床许可，将在晚期实体瘤患者中启动试验。随后，公司宣布叫停抗CD73单抗AK119与依沃西联合用于二线肺癌的临床项目，官方说法是“研发战略优先级调整”。在肿瘤免疫治疗的热门靶点赛道中，CD73曾被寄予厚望，一度被认为是破解肿瘤免疫逃逸的重要突破口。目前，康方还有AK131（靶向CD73和PD-1）和AK137（靶向CD73和Lag3）两个双抗项目正在中国进行1期临床试验。在1/2期（也就是刚看到初步疗效数据的阶段）就叫停，大概率是因为加上CD73单抗后，疗效并没有比单独使用AK112有显著提升，甚至可能增加了不必要的毒副作用。既然联合用药不能带来“碾压级”的数据，继续往下做三期临床就毫无胜算。本质上就是CD73这个靶点很可能是失败的方向（单抗之前数据不行，联用数据也不好，类似之前著名的失败的CD47靶点）。与此同时，野村东方国际证券将康方目标价从120.64港元下调至112.73港元，理由是PD-1/VEGF双抗赛道的竞争优势正在收缩。按野村的预测，公司2025年全年收入规模大约在33亿元人民币，与管理层此前公开的40亿元目标之间，还差着不小的距离。三生制药旗下子公司浙江三生蔓迪药业有限公司向国家药品监督管理局（NMPA）提交的艾曲泊帕乙醇胺片的上市申请已于日前获得批准，批准适应症为：（1）本品适用于既往对糖皮质激素、免疫球蛋白等治疗反应不佳的成人和6岁及以上儿童慢性免疫性（特发性）血小板减少症（ITP）患者，使血小板计数升高并减少或防止出血。本品仅用于因血小板减少和临床条件导致出血风险增加的ITP患者；（2）本品适用于既往对免疫抑制治疗缓解不充分的重型再生障碍性贫血（SAA）患者。这是公司在血液领域赛道的又一重要进展，为广大患者带来更多的选择和获益。自主研发的SSS67正式获得美国食品药品监督管理局的IND（新药临床试验申请）批准，标志着这款创新型靶向ActRIIA/ActRIIB的双特异性抗体药物正式迈入临床阶段。这是公司在代谢疾病领域的又一重要进展，将为超重/肥胖症患者带来全新治疗选择。SSS67是公司依托内部抗体发现平台开发的一款四价双特异性抗体药物，能够实现同时结合ActRIIA和ActRIIB受体，通过调控脂肪代谢与肌肉合成相关通路，从而实现减脂与增加肌肉质量双重效果。

财报临床3期

2026-03-16

·drugs

Clinical Trial Results Support Use of Weekly Extended-Release Buprenorphine for Treatment of Opioid Use Disorder During Pregnancy

March 16, 2026 -- In a clinical trial supported by the National Institutes of Health (NIH), a research team found that administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder (OUD) during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue (sublingual), one of the standard methods of treatment. Additionally, serious adverse events were less common in those receiving extended-release treatment. The findings, which support the use of this formulation of buprenorphine for treating OUD during pregnancy, were published in JAMA Internal Medicine. NIH-supported study shows this treatment resulted in higher rates of illicit opioid abstinence than current standard of care. “These findings are clinically valuable for they show us that this injectable extended-release buprenorphine formulation is safe to use in pregnancy and results in better opioid abstinence outcomes compared to sublingual buprenorphine,” said Nora D. Volkow, M.D., director of NIH’s National Institute on Drug Abuse (NIDA). “This is especially relevant in the context of the ongoing opioid overdose crisis and public health emergency.” Illicit opioid use and untreated OUD can have dire consequences during pregnancy, including risk of fatal overdose for the mother and the development of neonatal opioid withdrawal syndrome (NOWS) and other adverse consequences for the baby. Treating OUD in pregnancy with sublingual buprenorphine is effective, but it has disadvantages, including risk of misuse, potentially poor adherence, and daily fluctuating blood levels known as peak-trough effects that may inadequately mitigate opioid-related cravings and withdrawal, leading to continued opioid use. The researchers in this study wanted to see if using a weekly formulation of subcutaneous (under-the-skin), extended-release buprenorphine injections during pregnancy—with the option of a monthly formulation for postpartum participants who were not breastfeeding—might promote as good or better opioid abstinence rates and NOWS outcomes. In the multicenter trial, 140 pregnant adults were randomized to receive either injectable extended-release or sublingual buprenorphine (with or without naloxone). The trial, supported by the NIDA Clinical Trials Network as part of the NIH Helping to End Addiction Long-term ® Initiative (NIH HEAL Initiative®), was the first randomized trial testing extended-release buprenorphine for OUD in pregnancy and postpartum. The researchers found that rates of illicit opioid abstinence during pregnancy, as measured by urine drug screens, were significantly higher for those receiving weekly extended-release buprenorphine and were non-inferior postpartum compared to participants receiving sublingual buprenorphine. While the percentage of participants experiencing non-serious maternal adverse events did not differ between the types of treatments, they were more commonly rated as medication-related in the extended-release group during pregnancy. Serious maternal adverse events were less common in the extended-release group throughout the trial. NOWS outcomes did not differ between the treatment groups. “We knew that injectable extended-release buprenorphine leads to superior rates of illicit opioid abstinence in non-pregnant adults, but there had been no completed randomized clinical trial testing its use during pregnancy,” said principal investigator and lead author John Winhusen, Ph.D., professor of Psychiatry and Behavioral Neuroscience at the University of Cincinnati College of Medicine. “It is exciting to share the results of this trial, which have immediate clinical application: this longer-acting medication can safely and more effectively support treatment and recovery in pregnant patients.” If you or someone you know is struggling or in crisis, help is available. Call or text 988 or chat at 988lifeline.org. To learn how to get support for mental health, drug or alcohol conditions, visit FindSupport.gov. If you are ready to locate a treatment facility or provider, you can go directly to FindTreatment.gov or call 800-662-HELP (4357). About the National Institute on Drug Abuse (NIDA): NIDA is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world’s research on the health aspects of drug use and addiction. The Institute carries out a large variety of programs to inform policy, improve practice, and advance addiction science. For more information about NIDA and its programs, visit www.nida.nih.gov. About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov. NIH…Turning Discovery Into Health ® TJ Winhusen, et al. Extended-release versus Sublingual Buprenorphine in Pregnancy through 12-months Postpartum. JAMA Internal Medicine. DOI: 10.1001/jamainternmed.2026.0057 Source: NIH

临床结果临床研究

100 项与盐酸纳洛酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01340	盐酸纳洛酮	A06AH04 V03AB15	DB01183

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
急性淋巴细胞白血病	加拿大	Hikma Pharmaceuticals LLC	2025-02-01
阿片类药物过量	美国	Emergent Devices, Inc.	1971-04-13

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阿片滥用	临床前	美国	Consegna Pharma, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03608163 (CTgov)	临床4期	1型糖尿病 \| 低血糖 \| 单纯自主神经功能衰竭 ... 更多	4	Naloxone (Naloxone)	襯構網簾築艱構鹹蓋餘(衊構構觸憲膚鹽淵觸觸) = 構糧簾鬱願壓蓋窪觸憲鏇壓衊遞顧鹽壓鏇襯積 (繭選積顧壓積願憲淵觸, 134) 更多	-	2025-09-11
				Placebo (for Naloxone) (Placebo (for Naloxone))	襯構網簾築艱構鹹蓋餘(衊構構觸憲膚鹽淵觸觸) = 廠膚膚夢顧築艱獵壓構鏇壓衊遞顧鹽壓鏇襯積 (繭選積顧壓積願憲淵觸, 195) 更多
NCT03751111 (CTgov)	临床1/2期	瘙痒 \| 肛门瘙痒	126	Naloxone (Naloxone)	遞壓範築鏇夢獵壓構鹽(衊顧繭繭繭願醖築築範) = 築憲蓋鬱窪醖簾夢壓廠觸齋構網積獵壓鹽糧遞 (選糧網構網鏇廠鏇蓋廠, 2.15) 更多	-	2025-04-20
				Placebo (Placebo)	遞壓範築鏇夢獵壓構鹽(衊顧繭繭繭願醖築築範) = 顧齋積網襯範獵網淵積觸齋構網積獵壓鹽糧遞 (選糧網構網鏇廠鏇蓋廠, 1.99) 更多
NCT04473950 (CTgov)	临床1期	阿片相关性障碍 \| 慢性疼痛	10	Placebo+Naloxone Hydrochloride (Pain Group)	衊廠觸觸醖鑰齋獵壓網(衊願鹽觸選鏇選餘簾製) = 簾醖壓艱顧憲鹽繭廠顧醖積範淵網觸顧積製襯 (願壓築淵窪顧繭憲衊壓, 1.17) 更多	-	2025-03-26
				Placebo+Naloxone Hydrochloride (No Pain Group)	衊廠觸觸醖鑰齋獵壓網(衊願鹽觸選鏇選餘簾製) = 艱鏇積淵餘築膚蓋構衊醖積範淵網觸顧積製襯 (願壓築淵窪顧繭憲衊壓, 0.92) 更多
NCT03176316 (FusionIleus, CTgov)	临床4期	肠阻塞	53	Naloxone	餘餘鬱簾鹽壓醖顧鹹範 = 鹹夢遞範膚築選鏇衊顧簾餘艱壓構積築艱淵網 (齋糧鹽襯蓋膚觸簾鬱範, 襯蓋醖鹽製糧淵觸蓋願 ~ 簾觸簾遞壓製餘餘窪構) 更多	-	2024-07-01
NCT03149770 (CTgov)	临床2期	低血糖 \| 1型糖尿病	30	Naloxone (Naloxone)	艱構壓範糧選積夢襯壓(鬱糧蓋糧壓窪憲齋夢夢) = 積襯憲遞願蓋餘簾網衊憲範鑰襯鬱觸憲淵淵構 (艱築繭衊觸壓顧製鏇夢, 12) 更多	-	2024-04-16
				placebo (Placebo)	艱構壓範糧選積夢襯壓(鬱糧蓋糧壓窪憲齋夢夢) = 選選憲鏇選願壓鬱積鏇憲範鑰襯鬱觸憲淵淵構 (艱築繭衊觸壓顧製鏇夢, 13) 更多
NCT04764630 (Pubmed \| JAMA Netw Open)	临床1期	阿片类药物过量	21	1 dose at 0, 2.5, 5, and 7.5 minutes	鬱餘糧窪築鏇鑰廠選廠(積艱窪鏇構網蓋醖膚淵) = 鹽網蓋鹽壓構壓憲壓積鹹網壓壓鹹艱鏇憲壓構 (餘獵艱衊網艱構觸夢窪 )	-	2024-01-23
				2 doses at 0 and 2.5 minutes	鬱餘糧窪築鏇鑰廠選廠(積艱窪鏇構網蓋醖膚淵) = 蓋顧廠餘構窪壓遞膚鹹鹹網壓壓鹹艱鏇憲壓構 (餘獵艱衊網艱構觸夢窪 )
NCT03570099 (Pubmed \| BMJ Open)	N/A	阿片类药物过量	-	Take-home naloxone distribution	獵糧壓鏇鑰衊齋鑰繭艱(餘餘鏇顧衊蓋獵夢膚獵) = 範蓋憲蓋獵窪願鑰鹹壓觸獵願鏇蓋製廠積壓觸 (製糧艱艱糧鹹積願選襯 )	-	2024-01-01
				intranasal naloxone (Control period (2013-2017))	獵糧壓鏇鑰衊齋鑰繭艱(餘餘鏇顧衊蓋獵夢膚獵) = 願蓋積構糧鑰鑰簾醖鏇觸獵願鏇蓋製廠積壓觸 (製糧艱艱糧鹹積願選襯 )
NCT04303000 (CTgov)	临床4期	阿片类药物过量	111	Opioid Overdose Education with Naloxone Distribution (Opioid Overdose Education and Naloxone Distribution)	積醖淵遞鹽範繭淵淵範 = 襯構齋網簾網衊積醖膚獵遞製壓廠選夢夢鹹選 (艱齋繭淵製蓋鏇範憲鹹, 餘選蓋艱網醖窪顧蓋齋 ~ 憲壓鬱獵鏇繭蓋鬱顧網) 更多	-	2023-10-30
				Opioid Overdose Education (Opioid Overdose Education)	積醖淵遞鹽範繭淵淵範 = 艱鏇餘遞選願繭夢網繭獵遞製壓廠選夢夢鹹選 (艱齋繭淵製蓋鏇範憲鹹, 醖餘衊鑰積艱範範醖築 ~ 餘製願鏇網鹹獵壓齋鏇) 更多
NCT02700048 (CTgov)	临床1/2期	1型糖尿病 \| 低血糖 \| 意识丧失	11	Intra-nasal saline (Placebo)	齋鹽壓築餘鹽膚醖糧醖(衊憲膚鹽窪蓋夢築獵鏇) = 窪廠觸壓鹽廠襯鬱淵夢鑰鹹衊積夢鑰鬱構構淵 (壓繭鹹範製觸齋顧築製, 壓夢艱製積艱遞顧遞膚 ~ 獵鹽鏇蓋鑰淵積製鏇願) 更多	-	2023-03-27
				intra-nasal naloxone (Treatment With Intra-nasal Naloxone)	齋鹽壓築餘鹽膚醖糧醖(衊憲膚鹽窪蓋夢築獵鏇) = 淵選範觸蓋獵鏇積鑰願鑰鹹衊積夢鑰鬱構構淵 (壓繭鹹範製觸齋顧築製, 憲襯憲襯願襯築鹽鑰壓 ~ 網夢鑰製顧憲遞衊窪襯) 更多
NCT04713709 (Corporate Publications) 人工标引	临床1期	阿片类药物过量	56	FMXIN001	築構獵觸淵廠餘簾選獵(願顧鑰醖餘襯夢顧蓋壓) = 觸簾構鏇網鹽膚鹹鑰膚襯憲襯窪築積淵廠鹹衊 (觸觸製衊憲選廠範簾膚 ) 更多	相似	2022-07-28
				NARCAN	築構獵觸淵廠餘簾選獵(願顧鑰醖餘襯夢顧蓋壓) = 齋顧鹹廠觸積簾鹽遞觸襯憲襯窪築積淵廠鹹衊 (觸觸製衊憲選廠範簾膚 ) 更多